{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Binding antibody positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Neutralizing antibody positive"}],"denoms":[{"counts":[{"groupId":"OG000","value":"171"}],"units":"Participants"}],"description":"Anti-blinatumomab binding antibodies were evaluated using a validated electrochemiluminescence (ECL)-based assay (binding assay). Samples positive for binding were analyzed using a cell-based bioassay to determine if the detected antibodies had neutralizing properties (neutralizing assay).","groups":[{"description":"Participants received blinatumomab by continuous intravenous infusion (CIVI) over 4 weeks followed by a 2 week treatment-free interval for 2 induction cycles. Participants who achieved a bone marrow response, complete remission, or complete remission with partial or incomplete hematologic recovery (CR/CRh\\*/CRi) within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.\n\nParticipants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh\\*/CRi could continue to receive blinatumomab for an additional 12 months (4 cycles), where 1 cycle consisted of 4 weeks of CIVI followed by an 8-week treatment-free period.\n\nThe initial dose of blinatumomab was 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 through day 29 and for all subsequent cycles.","id":"OG000","title":"Blinatumomab"}],"paramType":"NUMBER","populationDescription":"Participants who received blinatumomab with available post-baseline antibody data.","reportingStatus":"POSTED","timeFrame":"Samples were collected on day 29 at the end of cycle 2 and 30 days after the last dose of blinatumomab (median duration of treatment was 70 days).","title":"Number of Participants With Anti-blinatumomab Antibodies","type":"SECONDARY","unitOfMeasure":"participants"}